Addressing Drug Diversion
|
|
- Darleen Sanders
- 5 years ago
- Views:
Transcription
1 Webinar Objectives Addressing Drug Diversion Bernice Burkarth, MD, HMDC, FAAHPM October12, 2017 At the completion of this Webinar, participants will be able to: Identify tools and strategies to minimize drug diversion in the practice of hospice and palliative care Discuss electronic tools used in prescribing controlled substances in hospice and palliative care Discuss strategies to identify and address both patient and family drug diversion CDC Prescriber Education PRESCRIPTION PAIN KILLER OVERDOSES AT EPIDEMIC LEVELS CDC press release November 1, 2011 Overdoses involving prescription painkillers are at epidemic levels and now kill more Americans than heroin and cocaine combined, CDC Director Thomas Frieden, M.D., M.P.H. The SCOPE of PAIN Safe and Competent Opioid Prescriber Education Boston University COPE Collaborative Opioid Prescribing Education Substance Abuse and Mental Health Services Administration American Academy of Addiction Psychiatry The 10 Steps of Universal Precautions in Pain Medicine 1. Make a Diagnosis With Appropriate Differential 2. Psychological Assessment, Including Risk of Addictive Disorders 3. Informed Consent 4. Treatment Agreement 5. Pre or Post Intervention Assessment of Pain Level and Function The 10 Steps of Universal Precautions in Pain Medicine 6. Appropriate Trial of Opioid Therapy With or Without Adjunctive Medication 7. Reassessment of Pain Score and Level of Function 8. Regularly Assess the "4 A's" of Pain Medicine 9. Periodically Review Pain Diagnosis and Comorbid Conditions, Including Addictive Disorders 10. Documentation Gourlay D, Heit HA, Universal precautions in pain medicine: The Treatment of Chronic Pain With or Without the Disease of Addiction. Medscape Neurology. 2005;7(1) 2005 Medscape Gourlay D, Heit HA, Universal precautions in pain medicine: The Treatment of Chronic Pain With or Without the Disease of Addiction. Medscape Neurology. 2005;7(1) 2005 Medscape 5 6 1
2 Opioid Risk Assessments Tools: prior to initiating long term therapy ORT (Opioid Risk Tool) SOAPP R (The Screener and Opioid Assessment for Patients with Pain Revised ) SISAP (Screening Instrument for Substance Abuse Potential) DIRE (The Diagnosis, Intractability, Risk, Efficacy) tool Opioid Risk Assessments Tools: monitoring for signs of opioid misuse in patients receiving long term opioid therapy PDUQ p (Prescription Drug Use Questionnaire patient version) COMM (Current Opioid Misuse Measure) PMQ (Patient Medication Questionnaire) Opioid Risk Assessments Tools: monitoring for signs of opioid misuse in patients receiving long term opioid therapy PADT (Pain Assessment and Documentation Tool) ABC (Action Behavior Checklist) Patient Provider Agreement Include as part of informed consent Incorporate drug disposal guidelines and expectations Inclusion of caregivers in agreement and accountability the "4 A's" of Pain Medicine Analgesia Activity Adverse effects Aberrant behaviors Pharmacologic Advances Abuse Deterrent Preparations Kenneth L. Kirsh, PhD; Steven D. Passik, PhD. Managing Drug Abuse, Addiction, and Diversion in Chronic Pain: The 4 A's for Ongoing Monitoring Medscape Neurology. 2005;7(2) 2005 Medscape 11 2
3 Electronic Tools Electronic Prescribing Organizational Processes Pill counts at every visit Providing lock boxes Random urine drug screen Prescription Drug Monitoring Programs 14 Organizational Processes Prescribing in smaller quantities Providing patient and caregiver education on safe storage of medications Providing patient and caregiver education on safe drug disposal FDA guidance Take back programs Medicines recommended for disposal by Abstral tablets (sublingual) Fentanyl Actiq oral transmucosal lozenge * Fentanyl Citrate Arymo ER, tablets (extended release) Morphine Sulfate Avinza capsules (extended release) Morphine Sulfate Belbuca soluble film (buccal) Buprenorphine Buprenorphine, tablets (sublingual) * Buprenorphine Buprenorphine ; Naloxone Buprenorphine ; Naloxone, tablets (sublingual) * Butrans transdermal patch system Buprenorphine ringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend Daytrana transdermal patch system Methylphenidate Demerol, tablets * Meperidine Demerol, oral solution * Meperidine Diastat/Diastat AcuDial, rectal gel [for disposal instructions: click on link, then go to "Label Diazepam information" and view current label] Dilaudid, tablets * Hydromorphone Dilaudid, oral liquid * Hydromorphone Dolophine tablets * Methadone Duragesic patch (extended release) * Fentanyl Embeda capsules (extended release) Morphine Sulfate; Naltrexone Exalgo tablets (extended release) Hydromorphone 17 ngsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend Fentora tablets (buccal) Fentanyl Citrate Hysingla ER tablets (extended release) Hydrocodone Bitartrate Kadian capsules (extended release) Morphine Sulfate Methadone, oral solution * Methadone Methadose, tablets * Methadone Morphabond (extended release) Morphine Sulfate Morphine Sulfate, tablets (immediate release) * Morphine Sulfate Morphine Sulfate oral solution * Morphine Sulfate MS Contin tablets (extended release) * Morphine Sulfate Nucynta ER (extended release) Tapentadol 18 suringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend 3
4 Onsolis (PDF 297KB), soluble film (buccal) Fentanyl Citrate Opana, tablets (immediate release) Oxymorphone Opana ER (extended release) Oxymorphone Oxecta, tablets (immediate release) Oxycodone Oxycodone, capsules Oxycodone Oxycodone oral solution Oxycodone Oxycontin tablets (extended release) Oxycodone Percocet, tablets * Acetaminophen; Oxycodone Percodan, tablets * Aspirin; Oxycodone Suboxone film (sublingual) Targiniq ER (extended release) Vantrela ER, tablets (extended release) Xartemis XR tablets Xtampza ER capsules (extended release) Xyrem oral solution Zohydro ER capsules (extended release) Zubsolv tablets (sublingual) Buprenorphine ; Naloxone Oxycodone ; Naloxone Hydrocodone Bitartrate Oxycodone ; Acetaminophen Oxycodone Sodium Oxybate Hydrocodone Bitartrate Buprenorphine ; Naloxone 19 nsuringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend uringsafeuseofmedicine/safedisposalofmedicines/ucm htm#recommend 20 Challenges: Whose drugs are they? In most states, hospices have little control over the pills after a patient dies. The U.S. Drug Enforcement Administration encourages hospice staff to help families destroy leftover medications, but the agency forbids those staff members from destroying the meds themselves unless that is allowed by state law. Leftover pills belong to the family, which has no legal obligation to destroy them or give them up Bailey, M. (2017, August 21). Dying at home in pain doesn t keep relatives from stealing the pills. Washingtonpost.com. Retrieved August 29, 2017, from science/dying at home in pain doesnt keep relatives from stealing the pills/2017/08/18/d262b9ba e7 902a 2a9f2d808496_story.html?utm_term=.4d33df79083f Getting Legislative Help Ohio Delaware New Jersey South Carolina These states have passed laws giving hospice staff authority to destroy unused drugs after patients die. Bailey, M. (2017, August 21). Dying at home in pain doesn t keep relatives from stealing the pills. Washingtonpost.com. Retrieved August 29, 2017, from science/dying at home in pain doesnt keep relatives from stealing the pills/2017/08/18/d262b9ba e7 902a 2a9f2d808496_story.html?utm_term=.4d33df79083f NHPCO on the Frontline: Supporting a National Policy and Uniform Set of Practices NHPCO has already drafted legislation and has been working with Congress to expand the ability of hospice professionals to take a more active role in helping families dispose of these drugs. Getting Legislative Help Advocating for cooperation with agencies that limit smaller, but more frequent prescription fills Medicaid VA NHPCO Response to KHN/Post. Edo Banach Responds to Kaiser Health News August 22,
5 Documentation Patient assessment Pain assessment The 4 A s of pain medicine Harris, DG. Management of Pain in Advanced Disease. British Medical Bulletin 2014, Teoha, Penelope J., Camm, Christian F. NICE Opioids in Palliative Care A Guideline Summary. Penelope J. Teoha, Christian F. Camm BA (Hons.). Annals of Medicine and Surgery 2012; 1(1): Portenoy, Russell K., Sibirceva, Una,Smout, Randall, Horn, Susan, Connor, Stephen, Blum, Ronald H.. Opioid Use and Survival at the End of Life: A Survey of a Hospice Population. Spence, Carol, Fine, Perry G. Journal of Pain and Symptom Management. Vol. 32 No. 6 December 2006 Review of medication safety guidelines 25 QUESTIONS Common Elements in Guidelines for Prescribing Opioids for Chronic Pain. CDC. National Center for Injury Prevention and Control Division of Unintentional Injury Prevention Edlund, Mark J., Martin Bradley C., Devries, Andrea, Fan, Ming Yu, Brennan Braden, Jennifer, Sullivan, Mark D. Trends in use of opioids for chronic noncancer pain among individuals with mental health and substance use disorders: the TROUP study. Clin J Pain January ; 26(1): 1 8 Chakravarthy Bharath, Shah, Shyam, Lotfipour, Shahram. Prescription Drug Monitoring Programs and Other Interventions to Combat Prescription Opioid Abuse. Western Journal of Emergency Medicine. Volume XIII, NO. 5 : November 2012 Throckmorton, Douglas C. Opioid Prescribing Practices and Pain Management: Role of FDA. American Academy of Hospice and Palliative Care Medicine. October, Gardiner, Clare; Gott, Merryn; Ingleton, Christine; Hughes, Philippa; Winslow, Michelle;. Bennett, Michael I. Attitudes of Health Care Professionals to Opioid Prescribing in End of Life Care: A Qualitative Focus Group Study. Journal of Pain and Symptom Management. Vol. 44 No. 2 August 2012 Bailey, M. (2017, August 21). Dying at home in pain doesn t keep relatives from stealing the pills. Washingtonpost.com. Retrieved August 29, 2017, from science/dying athome in pain doesnt keep relatives from stealing thepills/2017/08/18/d262b9ba e7 902a 2a9f2d808496_story.html?utm_term=.4d33df79083f Universal Precautions for Drug Misuse and Diversion in Hospice and Palliative Care Could an Ounce of Prevention Be Worth a Pound of Cure? (FR434) Cass, CleanneThomson, RuthBledsoe, RebeccaDurkin, Elizabeth et al. Journal of Pain and Symptom Management, Volume 49, Issue 2, Kenneth L. Kirsh, PhD; Steven D. Passik, PhD. Managing Drug Abuse, Addiction, and Diversion in Chronic Pain: The 4 A's for Ongoing Monitoring Medscape Neurology. 2005;7(2) 2005 Medscape Dmitry M. Arbuck, MD, Timothy J. Atkinson, PharmD, BCPS, Martin D. Cheatle, PhD, Amber Fleming, PsyD, HSPP, Gary W. Jay, MD, Lee Kral, PharmD, Amanda Macone, MD, Jordan L. Newmark, MD, Chinyere Ogbonna, MD, MPH, James A.D. Otis, MD, MBA, Tracey L. Perkins, RN, MSN, FNP C, Jennifer H. Scruggs, RN, MSN, ANP BC, Tejinder Swaran Singh, MD, Forest Tennant, MD, DrPH, Bob Twillman, PhD, Opioid Prescribing and Monitoring: How to Combat Opioid Abuse and Misuse Responsibly 5
6 Edlund M, Martin B, Russo J, et al. The role of opioid prescription in incident opioid abuse and dependence among individuals with chronic non cancer pain: the role of opioid prescription. Clin J Pain. 2014;30(7):
Disposal of Unused Medicines: What You Should Know
1 of 8 3/12/16 11:14 PM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page Overview List of Medicines Recommended
More informationDisposal of Unused Medicines: What You Should Know
1 of 8 04/27/2016 1:37 AM U.S. Food and Drug Administration Protecting and Promoting Your Health Disposal of Unused Medicines: What You Should Know Topics on this page (http://www.fda.gov/aboutfda/aboutthiswebsite
More informationHow To Green My Pharmacy. Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist
How To Green My Pharmacy Prepared and presented by Luna El Bizri,Pharm-D, Community Pharmacist Learning Objectives At the end of this presentation, pharmacists will be able to : 1. Understand the negative
More informationDisposal by Flushing of Certain Unused Medicines: What
Disposal by Flushing of Certain Unused Medicines: What You Should Know Drugs Page 1 of 5 Disposal by Flushing of Certain Unused Medicines: What You Should Know Overview Frequently Asked Questions List
More information20/0.8mg, 30/1.2mg, Films 90 MME/day Belbuca (buprenorphine) 75mcg, 150mcg, 300mcg, 450mcg 60 units per 90 days
Pre - PA Allowance Quantity Extended Release Tablets or Capsules 90 MME/day Medication Strength Avinza (morphine) 60mg, 75mg, 90mg Embeda (morphine /naltrexone) 50/2mg, 60/2.4mg, 80/3.2mg Exalgo (hydromorphone)
More informationCarefirst. +.V Family of health care plans
Family of health care plans Prior Authorization Form 1361M Opioids ER MME Limit and Post Limit This fax machine is located in a secure location as required by HPAA regulations. Complete/review information,
More informationOpioid Management Program October 2018
Opioid Management Program October 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationLong-Acting Opioid Analgesics
Market DC Long-Acting Opioid Analgesics Override(s) Prior Authorization Step Therapy Quantity Limit Approval Duration Initial request: 3 months Maintenance Therapy: Additional prior authorization required
More informationOpioid Management Program May 2018
Opioid Management Program May 2018 What Is the Opioid Management Program? This program is based on guidelines developed by the U.S. Centers for Disease Control and Prevention (CDC). It consists of daily
More informationPharmacy Medical Necessity Guidelines: Opioid Analgesics
Pharmacy Medical Necessity Guidelines: Effective: January 1, 2019 Prior Authorization Required Type of Review Care Management Not Covered Type of Review Clinical Review Pharmacy (RX) or Medical (MED) Benefit
More informationPequot Health Care Opioid Analgesic Quantity Program*
Pequot Health Care 1 Annie George Drive Mashantucket, CT 06338 Phone: 1-888-779-6638 Fax: 1-860-396-6494 Pequot Health Care Opioid Analgesic Quantity Program* Effective January 2018 *Quantity Program limits
More informationCapital BlueCross Open/Closed Formulary Update (1 st Quarter 2017)
Capital BlueCross Open/Closed Formulary Update (1 st Quarter 2017) The Capital BlueCross formulary is a reference list of prescription drugs that contains a wide range of generic and brand drugs that have
More informationPrior Authorization for Opioid Products Indicated for Pain Management
Kansas Medical Assistance Program PA Phone 800-933-6593 PA Fax 800-913-2229 Amerigroup PA Pharmacy Phone 855-201-7170 PA Pharmacy Fax 800-601-4829 Sunflower PA Pharmacy Phone 877-397-9526 PA Pharmacy Fax
More informationPrior Authorization Guideline
Guideline GL-35952 Opioid Quantity Limit Overrides Formulary OptumRx Formulary Note: Approval Date 7/10/2017 Revision Date 7/10/2017 Technician Note: P&T Approval Date: 2/16/2010; P&T Revision Date: 7/12/2011
More informationAPPROVED PA CRITERIA. Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION
Initial Approval: January 10, 2018 Revised Dates: April 11, 2018 CRITERIA FOR PRIOR AUTHORIZATION PROVIDER GROUP Pharmacy Opioid Products Indicated for Pain Management MANUAL GUIDELINES All dosage forms
More informationPharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers
Pharmacological Pain Management, the Evolving Role of Opioids, and Improving Education of Health Care Providers James P. Rathmell, M.D. Chair, Department of Anesthesiology, Perioperative and Pain Medicine
More informationQUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA
DRUG CLASS QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME (generic) ARYMO ER (morphine sulfate extended-release tablets) AVINZA (morphine extended-release
More informationMEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111
POLICY: Medicare Part D Formulary-Level Cumulative Opioid and Opioid/Buprenorphine POS Edits MEDICARE Program Policies & Procedures POLICY NUMBER: Medicare D-111 Policy for contracts H3351, S3521 and H3335
More informationOpioids, Extended Release (ER) Quantity Limit Criteria Program Summary
Opioids, Extended Release (ER) Quantity Limit Criteria Program Summary This program applies to Commercial, GenPlus, NetResults A series, Netresults F series and Health Insurance Marketplace. Belbuca is
More information: Opioid Quantity Limits
March 7, 2017 2017-09: Opioid Quantity Limits The Louisiana Department of Health (LDH), in conjunction with the Louisiana Medicaid Drug Utilization Review (DUR) Board, has revised quantity limits for selected
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2017 P 3053-7 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationUnitedHealthcare Pharmacy Clinical Pharmacy Programs
UnitedHealthcare Pharmacy Clinical Pharmacy Programs Program Number 2018 P 3053-9 Program Step Therapy Long Acting Opioids Medication Includes both brand and generic versions of the listed products unless
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Controlled Substance Analgesic and Narcotic Antagonist Quantity Limitations Table of Contents Coverage Policy... 1 General Background... 6 Coding/Billing
More informationGeneric Label Name Drug Strength Dosage Form Example Product (s) MME/Unit ACETAMINOPHEN WITH CODEINE
STATE OF TENNESSEE DEPARTMENT OF FINANCE AND ADMINISTRATION DIVISION OF HEALTH CARE FINANCE AND ADMINISTRATION BUREAU OF TENNCARE 3 Great Circle Road NASHVILLE, TENNESSEE 37243 This notice is to advise
More informationLong-Acting Opioid. Policy Number: Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018
Long-Acting Opioid Policy Number: 5.02.519 Last Review: 12/2017 Origination: 09/2013 Next Review: 09/2018 Policy Blue Cross and Blue Shield of Kansas City (Blue KC) will provide coverage for long-acting
More informationEXTENDED RELEASE OPIOID DRUGS
RATIONALE FOR INCLUSION IN PA PROGRAM Background Hydrocodone (Hysingla ER, Vantrela ER, Zohydro ER), hydromorphone (Exalgo), morphine sulfate (Arymo ER, Avinza, Embeda, Kadian, MorphaBond, MS Contin),
More informationOpioid Analgesics. Recommended starting dose for opioid-naïve patients
Opioid Analgesics Goals: Restrict use of opioid analgesics to OHP-funded conditions with documented sustained improvement in pain and function and with routine monitoring for opioid misuse and abuse. Promote
More informationOpioid Prescribing Guidelines for Patients in the Emergency Department
Opioid Prescribing Guidelines for Patients in the Emergency Department and Immediate Care Centers These guidelines are meant to assist clinicians in treating patients with acute and chronic pain in the
More informationCigna Drug and Biologic Coverage Policy
Cigna Drug and Biologic Coverage Policy Subject Opioid Therapy Table of Contents Coverage Policy... 1 General Background... 4 Coding/Billing Information... 7 References... 7 Effective Date..1/1/2018 Next
More informationPrior Authorization Opioid Overutilization 2017
Drugs Requiring Prior Authorization Label Name ACETAMINOPHEN/CAFFEINE/DIHYDROCODEINE CAPSULE ACETAMINOPHEN/CODEINE SOLUTION ACETAMINOPHEN/CODEINE TABLET ASCOMP/CODEINE CAPSULE BUTALBITAL/CAFFEINE/ACETAMINOPHEN/CODEINE
More informationSTEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA. AVINZA (morphine extended-release capsules)
Carelirst. +.V Family of health care plans cvs caremarktm STEP THERAPY WITH QUANTITY LIMIT AND POST LIMIT PRIOR AUTHORIZATION CRITERIA DRUG CLASS EXTENDED-RELEASE OPIOID ANALGESICS BRAND NAME* (generic)
More informationXyrem (Sodium Oxybate)
Texas Prior Authorization Program Clinical Criteria Drug/Drug Class Clinical Criteria Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Opioids, Extended Release (ER) Page 1 of 12 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Opioids, Extended Release (ER) Prime Therapeutics will review Prior Authorization
More informationMorphine Sulfate Hydromorphone Oxymorphone
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.02.33 Subject: Morphine Drug Class Page: 1 of 8 Last Review Date: June 19, 2015 Morphine Sulfate Hydromorphone
More informationPreventing Prescription Opioid Misuse Among Student Athletes
Preventing Prescription Opioid Misuse Among Student Athletes Massachusetts is in the midst of an opioid epidemic. Athletes in particular, due to their risk of injury and the resulting pain, may be at risk
More informationSee Important Reminder at the end of this policy for important regulatory and legal information.
Clinical Policy: Reference Number: CP.CPA.259 Effective Date: 11.16.16 Last Review Date: 11.17 Line of Business: Commercial Revision Log See Important Reminder at the end of this policy for important regulatory
More informationEmbeda. Embeda (morphine sulfate and naltrexone hydrochloride) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.39 Subject: Embeda Page: 1 of 6 Last Review Date: March 18, 2016 Embeda Description Embeda (morphine
More informationAETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization
AETNA BETTER HEALTH Prior Authorization guideline for Narcotic Analgesic Utilization Policy applies to all formulary and non-formulary schedules II V opioid narcotics, including tramadol and codeine, as
More informationMedication Policy Manual. Topic: Extended-release (ER) Opioid Medication Products for Pain. Date of Origin: January 1, 2018
Independent licensees of the Blue Cross and Blue Shield Association Medication Policy Manual Topic: Extended-release (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1,
More informationOpioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital
Opioid Capture in the AHSQC Can we reduce use by measuring it? Michael Reinhorn MD, MBA, FACS Dept of Surgery, Newton Wellesley Hospital Disclosure Davol/Bard Consultant Medtronic Physician Advisory Honorarium
More informationBlueprint for Prescriber Continuing Education Program
CDER Final 10/25/11 Blueprint for Prescriber Continuing Education Program I. Introduction: Why Prescriber Education is Important Health care professionals who prescribe extended-release (ER) and long-acting
More informationPrescription Drug Abuse: Colorado and Nationwide
Prescription Drug Abuse: Colorado and Nationwide Eric Lavonas, MD Associate Director, Rocky Mountain Poison and Drug Center Associate Professor, University of Colorado School of Medicine 1 What s the Problem?
More informationSession VI. Presenter Disclosure Information. Learning Objectives for Session VI. Prescribing Information. Prescribers Must Be Knowledgeable
SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4 6pm SPEAKERS Charles Argoff, MD, FABPM Michael Brennan, MD, FACP, FASAM Jeffrey Gudin, MD Presenter Disclosure Information The
More information1/29/2013. Schedule II Controlled Substances: Basics and Beyond. Controlled Substances. Controlled Substances, Schedule I
chedule II Controlled ubstances: Basics and Beyond James L. Besier, Ph.D., R.Ph., FAHP Adjunct Associate Professor College of Nursing Adjunct Assistant Professor James L. Winkle College of Pharmacy University
More informationStephanie E. Hughes, P.E. (408)
Stephanie E. Hughes, P.E. (408) 499-9271 steifehughes@yahoo.com www.stephaniehughes.net Learning Objectives Understand the environmental and social burdens of pharmaceutical waste Recognize the complexity
More informationResponding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team
Responding to the Opioid Epidemic: Behavioral Health Specialists Role on the Interprofessional Team Cheryl L Mejta, Ph.D. Nancy H Burley, Ed.D. Serena Wadhwa, Psy. D., LCPC, RYT, CADC Objectives Identify
More informationDemerol (meperidine oral tablet, oral solution), Meperitab (oral tablet)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subsection: Analgesics and Opioids Original Policy Date: May 8, 2015 Subject: Meperidine Page: 1 of 5 Last
More informationMedication Policy Manual. Date of Origin: January 1, Topic: Extended-release (ER) Opioid Medication Products for Pain
Medication Policy Manual Topic: Extendedrelease (ER) Opioid Medication Products for Pain Policy No: dru515 Date of Origin: January 1, 2018 Committee Approval Date: January 19. 2018 Next Review Date: December
More informationOpioids: Use and Misuse/Steven Feinberg, MD; Scott Levy, MD, MPH, FACOEM
Western Occupational Health Conference September 14, 2012 Opioid - Use & Misuse Scott Levy, MD MPH FACOEM Steven Feinberg, MD, MPH Disclosure Information Western Occupational Health Conference 2012 Steven
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationOpiate/Benzodiazepine/Muscle Relaxant Combinations
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Opiate/Benzodiazepine/Muscle Relaxant Combinations Clinical Edit Information Included in this Document Drugs requiring prior authorization:
More informationInterprofessional Webinar Series
Interprofessional Webinar Series Opioids in the Medically Ill: Principles of Administration Russell K. Portenoy, MD Chief Medical Officer MJHS Hospice and Palliative Care Director MJHS Institute for Innovation
More informationEquianalgesic Dosing of Opioids for Pain Management
PL Detail-Document #300405 This PL Detail-Document accompanies the related article published in PHARMACIST S LETTER / PRESCRIBER S LETTER April 2014 Equianalgesic Dosing of Opioids for Pain Management
More informationRisk Reduction Strategies in Pain Management
Risk Reduction Strategies in Pain Management Melissa J. Durham, PharmD, MACM, BCACP, DAAPM Assistant Professor of Clinical Pharmacy USC School of Pharmacy Clinical Pharmacist, The USC Pain Center Learning
More informationMethadone. Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.41 Subject: Methadone Page: 1 of 8 Last Review Date: March 18, 2016 Methadone Description Dolophine
More informationPharmacy Management Drug Policy
SUBJECT: Opioid Management Health and Safety Program POLICY NUMBER: PHARMACY-34 EFFECTIVE DATE: 6/2007 LAST REVIEW DATE: 07/01/2018 If the member s subscriber contract excludes coverage for a specific
More informationSession II. Learning Objectives for Session II. Key Principles of Safe Prescribing. Benefits and Limitations of ER/LA Opioids
Learning Objectives for Session II Session II Best Practices for How to Start Therapy with ER/LA Opioids, How to Stop, and What to Do in Between Upon completion of this module, the participants will be
More informationER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care
ER/LA Opioid REMS: Achieving Safe Use While Improving Patient Care In August 2014, the Food and Drug Administration (FDA) updated the Extended- Release/Long Acting Opioids REMS Blueprint (BP). CO*RE has
More informationPRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select Formulary October 1, 2018 Updates. Formulary. Alternatives
PRESCRIPTION DRUG PROGRAM FORMULARY UPDATES Select October 1, 2018 Updates Drug Name efavirenz 600mg (Brand = Sustiva ) trientine (Brand = Syprine ) hydrocortisone lot 0.1% (Brand = Locoid ) sumatriptan-naproxen
More information2/21/2018. What are Opioids?
Opioid Crisis: South Carolina Responds Carolyn Bogdon, MSN, FNP-BC Coordinator for Emergency Department Medication Assisted Treatment Program Medical University of South Carolina Opioid Crisis: A Mounting
More informationIntroduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics
Introduction for the FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics In April 2011, FDA announced the elements of a Risk Evaluation and Mitigation Strategy
More informationNucynta IR/ Nucynta ER (tapentadol immediate-release and extendedrelease)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Nucynta Page: 1 of 7 Last Review Date: March 18, 2016 Nucynta Description Nucynta IR/ Nucynta
More information15 mg morphine 10 mg hydrocodone
Cari untuk: Cari Cari 15 mg morphine 10 mg hydrocodone 3-2-2013 Convert From CALCULATED MORPHINE EQUIVALENT BY RESOURCE: Average ( mg ) Range ( mg ) Standard Deviation of Sample ( mg ) Hydrocodone. I usually
More informationDrug Use Evaluation: Short Acting Opioids (SAO)
Drug Use Evaluation: Short Acting Opioids (SAO) Summary Short acting opioid analgesics are one of the most prescribed (top 10) and highest cost (top 20) medication classes for the Oregon Fee For Service
More informationDuragesic patch. Duragesic patch (fentanyl patch) Description
1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.31 Subject: Duragesic patch Page: 1 of 6 Last Review Date: March 18, 2016 Duragesic patch Description Duragesic patch (fentanyl
More informationExtended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Section: Prescription Drugs Effective Date: January 1, 2019 Subject: Extended Release Opioid Drugs Page:
More informationDrug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA opioid analgesics) Avinza Butrans
FDA Blueprint for Prescriber Education for Extended-Release and Long-Acting Opioid Analgesics 7/9/2012 Drug Information Common to the Class of Extended-Release and Long-Acting Opioid Analgesics (ER/LA
More informationOpioid Prescription and Illicit Drug Overdoses: On the Rise
Opioid Prescription and Illicit Drug Overdoses: On the Rise Cindy Haynes, MSA-PA, CHES Chronic Pain Program Coordinator Northern Piedmont Community Care Duke Division of Community Health Objectives Define
More information``Considerations for using opioid drug therapy in workers compensation include patient safety, drug effectiveness and financial impacts
Opioids Effective Case Management Opioids RELEVANCE IN WORKERS COMP Opioids are a diverse group of drugs that represent the strongest pain medications available. They are frequently prescribed for pain
More informationOpioid Analgesic Treatment Worksheet
Opioid Analgesic Treatment Worksheet Aetna Better Health of Louisiana Fax: 1 844 699 2889 www.aetnabetterhealth.com/louisiana/providers/pharmacy LA Legacy Fee for Service (FFS) Medicaid Fax: 1 866 797
More informationExtended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 14 Last Review Date: March 16, 2018 Extended
More informationLimitations of use: Subsys may be dispensed only to patients enrolled in the TIRF REMS Access program (1).
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.21 Subject: Subsys Page: 1 of 5 Last Review Date March 17, 2017 Subsys Description Subsys (fentanyl
More informationTexas Prior Authorization Program Clinical Edit Criteria
Texas Prior Authorization Program Clinical Edit Criteria Drug/Drug Class Clinical Edit Information Included in this Document Drugs requiring prior authorization: the list of drugs requiring prior authorization
More informationNew Hampshire Healthy Families CLINICAL POLICY
New Hampshire Healthy Families CLINICAL POLICY DEPARTMENT: Pharmacy DOCUMENT NAME: Opioid Analgesics PAGE: 1 o f 6 REFERENCE NUMBER: NH.PPA.13 EFFECTIVE DATE: 6/1/2016 REPLACES DOCUMENT: N/A RETIRED: REVIEWED:
More informationBreakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights
Breakthrough Cancer Pain (BTCP) 25 Years of Study: Key Insights Steven Wong, MD Assistant Professor of Medicine, Department of Medicine, Division of Hematology/Oncology, UCLA David Geffen School of Medicine
More informationRecognizing Narcotic Abuse and Addiction and Helping Those With It
Recognizing Narcotic Abuse and Addiction and Helping Those With It Michael McNett, MD Medical Director for Chronic Pain Member, WI Med Society Opioid Subcommittee Ancient History 1995: OxyContin approved
More informationHOPE. Considerations. Considerations ISING. Safe Opioid Prescribing Guidelines for ACUTE Non-Malignant Pain
Due to the high level of prescription drug use and abuse in Lake County, these guidelines have been developed to standardize prescribing habits and limit risk of unintended harm when prescribing opioid
More informationOPIOID IDENTIFICATION GUIDE
OPIOID IDENTIFICATION GUIDE WHAT ARE OPIOIDS, PRESCRIPTION PAINKILLERS, OR NARCOTICS? Rx Rx Rx Rx The Prescription Playbook Rx The Prescription Playbook is an education and awareness campaign for parents
More informationDrug Formulary Commission
Drug Formulary Commission Bureau of Health Care Safety and Quality Department of Public Health December 15, 2016 Slide 1 Presentation Agenda Draft Formulary (105 CMR 720) Schedule Amendments Comments Guidance
More informationVirtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4:
Virtual Mentor American Medical Association Journal of Ethics April 2014, Volume 16, Number 4: 279-283. POLICY FORUM OxyContin, the FDA, and Drug Control Gary M. Reisfield, MD One percent of people will
More informationCan Chronic Opioid Therapy Be Used Safely and Effectively for the Treatment of Chronic Pain? Charles E. Argoff, MD, CPE
Can Chronic Opioid Therapy Be Used Safely and Effectively for the Treatment of Chronic Pain? Charles E. Argoff, MD, CPE Disclosure Consultant/Independent Contractor Depomed, Teva, Endo, Purdue, Quest,
More informationSession VI. SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education. Presenter Disclosure Information. Presenting Faculty
Presenter Disclosure Information SAFE Opioid Prescribing Strategies. Assessment. Fundamentals. Education 4:15 5pm Getting the Most Clinical Insights from Specific ER/LA Product Information Sources SPEAKERS
More informationPRESCRIBING GUIDELINES
Ohio Department of Health RESPONSE TO OHIO S PRESCRIPTION DRUG OVERDOSE EPIDEMIC: PRESCRIBING GUIDELINES MIPA CONFERENCE PREVENTING INJURY: FROM RESEARCH TO PRACTICE TO PEOPLE SEPTEMBER 30, 2013 Christy
More informationOpioid Overview Admiral Brett P. Giroir, M.D.
A S S I S TA N T S E C R E TA RY F O R H E A LT H Opioid Overview Admiral Brett P. Giroir, M.D. Assistant Secretary for Health Senior Advisor for Opioid Policy @HHS_ASH August 20, 2018 SUBSTANCE ABUSE
More informationAbuse Deterrent Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017
Opioid Formulations Claire Saadeh, PharmD, BCOP / August 2017 Introduction 1,2 Dilemma: Providing balance between providing appropriate access to opioid products in patients who truly need them AND addressing
More informationPrescription Opioid Painkiller Public Opinion Poll
Prescription Opioid Painkiller Public Opinion Poll August, 2017 OBJECTIVES The overall objective of this research was to collect attitudes and views of prescription opioid painkillers among adults in Illinois.
More informationExtended-Release and Long- Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Presenter: Affiliation:
Extended-Release and Long- Acting Opioid Analgesics Risk Evaluation and Mitigation Strategy (REMS) Presenter: Affiliation: Faculty Disclosure FACULTY place your disclosure information on this slide Thank
More informationPAIN CONTROL IN THE PATIENT WITH ACUTE/CHRONIC PAIN JAY E. OLSSON,DO AOBPMR DCAQPM ABPMR ABPM
PAIN CONTROL IN THE PATIENT WITH ACUTE/CHRONIC PAIN JAY E. OLSSON,DO AOBPMR DCAQPM ABPMR ABPM Disclaimers Speaker Bureau Avanir Pharmaceuticals Nuedexta Pfizer Inc. Embeda Lyrica FOCUS Pharmacologic interventions
More informationNATL. II. Health Net Approved Indications and Usage Guidelines: Diagnosis of cancer AND. Member is on fentanyl transdermal patches AND
Coverage of drugs is first determined by the member s pharmacy or medical benefit. Please consult with or refer to the Evidence of Coverage document I. FDA Approved Indications: The management of breakthrough
More informationConversion chart from fentanyl to opana er
Conversion chart from fentanyl to opana er (e.g., Nucynta). Both opioid products involved in conversion are one of the following: morphine, oxycodone, oxymorphone, hydromorphone (not extended- release),
More informationExtended Release Opioid Drugs
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.61 Subject: Extended Release Opioid Drugs Page: 1 of 13 Last Review Date: December 8, 2017 Extended
More informationFENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA
FENTANYL CITRATE TRANSMUCOSAL UTILIZATION MANAGEMENT CRITERIA DRUG CLASS: BRAND (generic) NAMES: HICL = H3AT Fentanyl citrate transmucosal Actiq (fentanyl citrate) lozenge on a handle 200, 400, 600, 800,
More information4/3/2018. The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers. Learning Objectives
The Role of Pharmacists in the Safe Prescribing of Opioids: Having the Tough Talks with Patients and Prescribers Melissa Durham Tania Gregorian Vlada Manzur Learning Objectives Describe current issues
More informationThe Unseen Consequences of Prescription Drug Abuse. Stephen Loyd, M.D.
The Unseen Consequences of Prescription Drug Abuse Stephen Loyd, M.D. Stephen Loyd, M.D. Receives no commercial support, in any form, from pharmaceutical companies or anyone else Medical Director for Substance
More informationEducation Program for Prescribers and Pharmacists
Transmucosal Immediate Release Fentanyl (TIRF) Products Risk Evaluation and Mitigation Strategy (REMS) Education Program for Prescribers and Pharmacists Products Covered Under this Program Abstral (fentanyl)
More informationTechnician Tutorial: Scheduled Drugs
(Page 1 of 8) Technician Tutorial: Scheduled Drugs In the U.S., the federal Controlled Substances Act (CSA) regulates controlled substances. The U.S. Drug Enforcement Administration (DEA), which is a part
More informationSpotlight on Health Policy Beyond the Clinical: The Opioid Epidemic. October 25, 2017
Spotlight on Health Policy Beyond the Clinical: The Opioid Epidemic October 25, 2017 Disclosures and Disclaimer Neither the Institute for Health Policy and Leadership (IHPL) nor I have any relevant financial
More informationOpioids: Use, Abuse and Cause of Death. Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory
Opioids: Use, Abuse and Cause of Death Jennifer Harmon Assistant Director - Forensic Chemistry Orange County Crime Laboratory jharmon@occl.ocgov.com Opioid: Any psychoactive chemical that resembles morphine
More information